Objective:To observe the effect of different dosages of ligustrazine(LG)on the level ofplasminogen activator inhibitor-1(PAI-1)activity in patients with type 2 diabetes mellitus.Methods:Ninety cases of type 2 diabetes mellitus inpatients were selected,and randomly divided into LG small dos-age group(SDG),LG large dosage group(LDG)and control group.The 120 mg LG,400 mg LG andnormal saline 250 ml were given through intravenous dripping respectively,once daily,20 days as onetreatment course. Before and after treatment,all the patients had their fasting blood taken for PAI-1 andtissue plasminogen activator(t-PA)assessment test to perform the comparative study.Results:Seventy-three out of the 90 patients completed the observation course,the PAI-1 activity of three groups aftertreatment all lowered compared with that before treatment,and the difference between groups was alsosignificant(all P<0.01).After treatment the PAI-1 level of SDG and LDG of LG were all markedly low-ered(all P<0.01),the LDG’s lowering Objective: To observe the effect of different dosages of ligustrazine (LG) on the level of plasma activator inhibitor-1 (PAI-1) activity in patients with type 2 diabetes mellitus. Methods: Ninety cases of type 2 diabetes mellitus in patients were selected, and LG divided into LG small dos-age group (SDG), LG large dosage group (LDG) and control group. 120 mg LG, 400 mg LG and normal saline 250 ml were given intravenous dripping respectively, once daily, 20 days as onetreatment course. Before and after treatment, all the patients had their fasting blood for PAI-1 and tissue plasminogen activator (t-PA) assessment test to perform the comparative study. Results: Seventy-three out of the 90 patients completed the observation course, the PAI-1 activity of three groups aftertreatment all lowered comparable with that before treatment, and the difference between groups was alsosificificant (all P <0.01). After treatment the PAI-1 level of SDG and LDG of LG were all markedly low-ered (all P <0.01), th e LDG’s lowering